<DOC>
	<DOCNO>NCT00441571</DOCNO>
	<brief_summary>The propose phase 1 clinical trial investigate safety tolerability 177Lu-CYT-500 patient metastatic prostate cancer determine optimal antibody mass dose 177Lu use study .</brief_summary>
	<brief_title>Safety Study Radiolabeled Antibody ( 7E11 ) Patients With Progressive Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description>The proposed phase I clinical trial investigate safety tolerability 177Lu-CYT-500 determine optimal antibody mass dose 177Lu use study . The biodistribution pharmacokinetics also assess . Patients histologically documented prostate cancer progress follow castration eligible . Two antibody mass explore cohort 1 dose escalation 177Lu begin . If two antibody mass show difference pharmacokinetics biodistribution , low dos use . The radiation dose escalate subsequent cohort . Dose escalation permit last patient accrue previous cohort demonstrate count recovery cycle 1 DLT define .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Histologically document prostate cancer progress follow castration . The disease progress require palliative treatment within 12 week enrollment base clinical assessment investigator . All patient must assessable disease radionuclide and/or radiographic study . Castrate level testosterone ( &lt; 50 ng/ml ) . Karnofsky performance status &gt; 60 % . Patients whose initial hormone treatment ( exclusive neoadjuvant hormone therapy ) combine androgen blockade approach , e.g . orchiectomy plus antiandrogen , gonadotropin release hormone analog antiandrogen , must show progression disease follow withdrawal antiandrogen prior enrollment . Adequate organ function : Hematologic : ANC &gt; 1,500/mm3 Platelet count &gt; 100,000/mm3 Hepatic : Bilirubin &lt; 1.5 mg/dL AST &lt; 1.5X 's ULN Renal : Creatinine &lt; 1.5 mg/dL creatinine clearance &gt; 60 mL/min . Coagulation : Prothrombin time &lt; institutional UNL . Patients must recover acute toxicity prior therapy , receive chemotherapy , radiation therapy investigational anticancer therapeutic drug least 4 week prior entry trial . Patients must least 18 year age . Subjects inform potential risk procreation participate trial advise use effective contraception entire study period . Patients must sign informed consent indicate aware investigational nature study keep policy institution . Clinically significant cardiac disease ( New York Heart Association Class III IV ) , severe debilitate pulmonary disease . Active CNS epidural primary tumor active CNS epidural metastasis . An active uncontrolled infection infection require intravenous antibiotic treatment . Participation another therapeutic clinical trial experimental drug , concurrently within 4 week prior dose study . Lack recovery myelosuppressive effect prior radiation therapy chemotherapy . Patients undergone diagnostic ProstaScint , Myoscint , Oncoscint scan , undergone prior administration murine protein diagnostic therapeutic purpose , without regard HAMA test result . Patients history autoimmune hepatitis history autoimmune disease . Prior radiation therapy encompass &gt; 25 % bone marrow Prior systemic administration therapeutic radiolabeled monoclonal antibody . Patients unwilling use condom ( even undergone prior vasectomy ) intercourse , take drug 4 week stop treatment .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>radiolabeled antibody</keyword>
</DOC>